Antiparasitic chemotherapy: tinkering with the purine salvage pathway.
about
The Leishmania donovani UMP Synthase Is Essential for Promastigote Viability and Has an Unusual Tetrameric Structure That Exhibits Substrate-controlled OligomerizationMycobacterial adenosine kinase is not a typical adenosine kinaseLeishmania infantum ecto-nucleoside triphosphate diphosphohydrolase-2 is an apyrase involved in macrophage infection and expressed in infected dogsSterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasisNatural Products as New Treatment Options for Trichomoniasis: A Molecular Docking Investigation.Metabolic reprogramming during purine stress in the protozoan pathogen Leishmania donovaniExpression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic propertiesGlycobiology of the Leishmania parasite and emerging targets for antileishmanial drug discovery.Genomic organization of leishmania species.Synthetic Medicinal Chemistry in Chagas' Disease: Compounds at The Final Stage of "Hit-To-Lead" Phase.Computational elucidation of structural basis for ligand binding with Leishmania donovani adenosine kinase.Molecular cloning, expression and enzymatic assay of pteridine reductase 1 from Iranian lizard Leishmania.Leishmania infantum 5'-Methylthioadenosine Phosphorylase presents relevant structural divergence to constitute a potential drug target.2'-Deoxyribosyltransferase from Leishmania mexicana, an efficient biocatalyst for one-pot, one-step synthesis of nucleosides from poorly soluble purine bases.Magnesium-Dependent Ecto-ATP Diphosphohydrolase Activity in Leishmania donovani.
P2860
Q27667488-FFCDE923-32DD-4494-A8B3-00DC0450DAD7Q28486733-74969DCC-6CC9-488E-A766-BC610DE285D3Q28544921-99112EAF-E247-497D-A4B0-D6C78C6C1E95Q28727454-E26385FD-1DD6-43CA-A3DD-AB75CC40808DQ33553302-C950C10E-98B5-411F-A80A-BC7B527BBA52Q35105624-8F4D5D5A-8FE8-4DA4-8FB1-C8F19F48409CQ37135480-3EEC6D70-EE7E-41DC-A001-E6F2AF326820Q37763950-379B2192-C689-4CCD-AA12-C36831301D68Q37985972-4D517A3F-217C-4284-AD3E-84EFB3D3C40FQ38974228-145CC9D8-C76E-42C8-B6C3-2817FF09C713Q41854104-BA519FA8-B285-4A8E-8FAB-50F7B16F6BE5Q42732972-008AD98B-E0A0-4F8F-81A8-18715AAEE04FQ47139107-D6AE1218-C0B9-49D4-8DB7-B01A10DED836Q47821783-776E8BFA-BF3C-4C9C-84C4-6312165B16A9Q51536256-7CCB10FA-C048-4F89-9B20-EE69A2C1B663
P2860
Antiparasitic chemotherapy: tinkering with the purine salvage pathway.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antiparasitic chemotherapy: tinkering with the purine salvage pathway.
@en
Antiparasitic chemotherapy: tinkering with the purine salvage pathway.
@nl
type
label
Antiparasitic chemotherapy: tinkering with the purine salvage pathway.
@en
Antiparasitic chemotherapy: tinkering with the purine salvage pathway.
@nl
prefLabel
Antiparasitic chemotherapy: tinkering with the purine salvage pathway.
@en
Antiparasitic chemotherapy: tinkering with the purine salvage pathway.
@nl
P2093
P1476
Antiparasitic chemotherapy: tinkering with the purine salvage pathway.
@en
P2093
Alok Kumar Datta
Banibrata Sen
Rupak Datta
P304
P356
10.1007/978-0-387-77570-8_10
P407
P577
2008-01-01T00:00:00Z